An Open-label, Exploratory Study Assessing the Feasibility of SGM-101, a Fluorochrome-labeled Anti-carcinoembryonic Antigen Monoclonal Antibody for the Intraoperative Detection of Lung Metastasis in Colorectal Cancer
试验速览
- 阶段
- 2 期
- 发起方
- 入组人数
- 10
- 试验地点
- 2
- 主要终点
- Ability of SGM-101 and a near-infrared camera system to detect colorectal lung metastases.
研究概览
简要总结
Near-infrared fluorescence-guided oncologic surgery (FGOS) with the use of a tumor specific tracer (SGM-101) developed by Surgimab can provide valuable intra-operative information about tumor location and extensiveness. SGM-101 already proven to be safe and valuable in colorectal cancer.
This study aims to prove feasibility for colorectal lung metastases.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Diagnostic
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —(Adult, Older Adult)
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Signed informed consent prior to any study-mandated procedure;
- •Patients aged over 18 years old;
- •All women of child bearing potential and all males must practice effective contraception during the study and be willing and able to continue contraception for at least 30 days after their last dose of study treatment.
- •Has the ability to communicate well with the Investigator in the Dutch language and willing to comply with the study restrictions.
- •Diagnosed with lung metastasis of colorectal origin and scheduled for a resection.
排除标准
- •History of any anaphylactic reaction;
- •Other malignancies either currently active or diagnosed in the last 5 years, except adequately treated in situ carcinoma of the cervix and basal or squamous cell skin carcinoma;
- •Laboratory abnormalities defined as:
- •Aspartate AminoTransferase, Alanine AminoTransferase, Gamma Glutamyl Transferase) or Alkaline Phosphatase levels above 5 times the or;
- •Total bilirubin above 2 times the ULN or;
- •Serum creatinine above 1.5 times the ULN or;
- •Platelet count below 100 x 109/L or;
- •Hemoglobin below 4 mmol/L (females) or below 5 mmol/l (males);
- •Known positive test for human immunodeficiency virus (HIV), hepatitis B surface antigen (HBsAG) or hepatitis C virus (HCV) antibody or patients with untreated serious infections;
- •Patients pregnant or breastfeeding (pregnancy should be ruled out by a pregnancy test within two weeks prior to administration of the conjugate);
- •Any condition that the investigator considers to be potentially jeopardizing the patient's well-being or the study objectives.
- •Previous SGM-101 use
研究组 & 干预措施
SGM-101
Patients included with colorectal lung metastases, SGM-101 7.5-12.5mg, 3-5 days prior to surgery
干预措施: SGM-101 (Drug)
结局指标
主要结局
Ability of SGM-101 and a near-infrared camera system to detect colorectal lung metastases.
时间窗: peroperative
Intraoperative imaging of colorectal lung metastases based on the tumor-to-background ratio
次要结局
未报告次要终点
研究者
Alexander Vahrmeijer
Principal Investigator
Leiden University Medical Center
